Article
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
Cancer discovery - 1 Mar 2021
Lam Hubert, McNeil Lisa K, Starobinets Hanna, DeVault Victoria L, Cohen Roger B, Twardowski Przemyslaw, Johnson Melissa L, Gillison Maura L, Stein Mark N, Vaishampayan Ulka N, DeCillis Arthur P, Foti James J, Vemulapalli Vijetha, Tjon Emily, Ferber Kyle, DeOliveira Daniel B, Broom Wendy, Agnihotri Parul, Jaffee Elizabeth M, Wong Kwok-Kin, Drake Charles G, Carroll Pamela M, Davis Thomas A, Flechtner Jessica Baker
Abstract excerpt
Neoantigens are critical targets of antitumor T-cell responses. The ATLAS bioassay was developed to identify neoantigens empirically by expressing each unique patient-specific tumor mutation individually in Escherichia coli, pulsing autologous dendritic cells in an ordered array, and testing the patient's T cells for recognition in an overnight assay. Profiling of T cells from patients with lung cancer revealed...
Topics
- Animals
- Antigens, Neoplasm
- Biomarkers, Tumor
- Cancer Vaccines
- Cell Line, Tumor
- Clinical Trials as Topic
- DNA Mutational Analysis
- Disease Models, Animal